Higher Midlife BMI Tied to Earlier Alzheimer's

This article originally appeared here.
Share this content:
Higher Midlife BMI Tied to Earlier Alzheimer's
Higher Midlife BMI Tied to Earlier Alzheimer's

WEDNESDAY, Sept. 2, 2015 (HealthDay News) -- Among elderly adults with Alzheimer's disease, those who were overweight at age 50 tended to develop dementia earlier, according to research published online Sept. 1 in Molecular Psychiatry.

The study findings come from a long-term review of 1,394 older adults who were free of dementia at the outset. Just over 10 percent were eventually diagnosed with Alzheimer's.

On average, the study participants were 83 years old when diagnosed with Alzheimer's. But that age of onset varied according to people's weight at age 50: For each unit increase in body mass index (BMI), Alzheimer's set in about seven months earlier, on average. After accounting for hypertension, hypercholesterolemia, diabetes mellitus, and smoking status, the team found that a higher BMI at age 50 was still connected to earlier Alzheimer's onset. Brain autopsies showed that Alzheimer's patients who'd been heavier in middle age generally had greater neuropathology.

Other studies have found that obesity may boost the risk of developing Alzheimer's. But this research suggests it also speeds the onset, senior researcher Madhav Thambisetty, M.D., Ph.D., of the U.S. National Institute on Aging, told HealthDay. It's not clear, however, whether those brain abnormalities are the reason for the earlier Alzheimer's, Thambisetty said. Plus, he noted, there were some factors that his team could not account for -- such as the quality of people's diets.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

WHO: Vaccine Hesitancy a Major Global Health Threat

WHO: Vaccine Hesitancy a Major Global Health Threat

Percentage of U.S. children 19 to 35 months who have not been vaccinated has quadrupled since 2001

FDA Down to 5 Weeks of Funding to Review New Drug Applications

FDA Down to 5 Weeks of Funding to ...

Agency cannot accept new fees or applications until the shutdown is over

FDA Approves First Generic Version of Epilepsy Drug Sabril

FDA Approves First Generic Version of Epilepsy Drug ...

Generic equivalents held to same vigorous manufacturing standards as brand-name drugs

is free, fast, and customized just for you!




Already a member?

Sign In Now »